24 April 2026
24 April 2026
The White House deal will see Regeneron offer all its new medicines at “MFN prices”, while providing Otarmeni for free to eligible patients.
UK Biobank data from all 500,000 participants within the charity’s health database was put up for sale on the Chinese e-commerce website Alibaba.
Innovative Molecules' adibelivir had a favourable pharmacokinetic profile and proved safe and efficacious in Phase I clinical trials.
Strong systems that enable trust and governance are key to enabling the growth of AI technologies in drug development.
Under the agreement, Apotex will acquire Cumberland's portfolio of branded medicines for cash.
Enanta is in a strong position to dominate the largely untapped RSV therapeutics market with a Phase III trial on the horizon.
The US Government will now pick up the cost of weight loss drugs offered through the Medicare GLP-1 Bridge scheme until 31 December 2027.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
